» Articles » PMID: 6848301

Cefazolin and Cephalexin Kinetics in Continuous Ambulatory Peritoneal Dialysis

Overview
Publisher Wiley
Specialty Pharmacology
Date 1983 Jan 1
PMID 6848301
Citations 12
Authors
Affiliations
Soon will be listed here.
Abstract

We studied single-dose cefazolin (CFZ) and cephalexin (CPX) kinetics in continuous ambulatory peritoneal dialysis (CAPD) patients to establish therapeutic guidelines for two cephalosporins commonly used to treat peritonitis in these patients. CFZ, 10 mg/kg, was given intravenously and intraperitoneally, while CPX, 500 mg, was given orally. CFZ led to serum concentrations of 25 microgram/ml at 24 hr, with a half-life (t 1/2) of 33 hr. CAPD accounted for only 20% of total body clearance. When CFZ was given intraperitoneally, 74% of the dose was absorbed and similar serum concentrations had much the same t 1/2. CPX, on the other hand, had a serum t 1/2 of 8.6 hr and resulted in much lower peritoneal concentrations than CFZ. The kinetic principal of superposition provided a model for the prediction of plasma concentrations after repeated intraperitoneal doses of CFZ. The model predicts that a 10-mg/kg intraperitoneal loading dose, followed by 5-mg/kg doses in each exchange the first day and 2.5-mg/kg doses thereafter, will lead to steady-state plasma concentrations of 50 to 65 microgram/ml. The data suggest that CFZ needs be given only intraperitoneally at doses lower than those in current use. CPX probably adds little to the treatment of peritonitis.

Citing Articles

A Systematic Review on the Clinical Pharmacokinetics of Cephalexin in Healthy and Diseased Populations.

Kanan M, Atif S, Mohammed F, Balahmar Y, Adawi Y, AlSaleem R Antibiotics (Basel). 2023; 12(9).

PMID: 37760698 PMC: 10526061. DOI: 10.3390/antibiotics12091402.


Pharmacokinetic aspects during continuous ambulatory peritoneal dialysis: a literature review.

Janknegt R, Koks C Pharm Weekbl Sci. 1984; 6(6):229-36.

PMID: 6393041 DOI: 10.1007/BF01954550.


Pharmacokinetics of ceftizoxime in patients undergoing continuous ambulatory peritoneal dialysis.

Burgess E, Blair A Antimicrob Agents Chemother. 1983; 24(2):237-9.

PMID: 6314887 PMC: 185144. DOI: 10.1128/AAC.24.2.237.


Drug therapy in patients undergoing peritoneal dialysis. Clinical pharmacokinetic considerations.

Paton T, Cornish W, MANUEL M, Hardy B Clin Pharmacokinet. 1985; 10(5):404-25.

PMID: 3899455 DOI: 10.2165/00003088-198510050-00003.


Moxalactam kinetics during continuous ambulatory peritoneal dialysis after intraperitoneal administration.

Jones T, Milne R, Mudaliar Y, Sansom L Antimicrob Agents Chemother. 1985; 28(2):293-8.

PMID: 3834835 PMC: 180234. DOI: 10.1128/AAC.28.2.293.